Prediction of efficacy of disease-modifying antirheumatic drugs, biologic agents and immunosupprresants for rheumatoid arthritis and collagen disease

Prediction of efficacy of disease-modifying antirheumatic drugs, biologic agents and immunosupprresants for rheumatoid arthritis and collagen disease - Prediction of immunosuppressants

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017557

Enrollment

720

Registered

2015-05-14

Start date

2009-12-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis, collagen disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who were diagnosed with RA, SLE, SSc, PM/DM, MCTD, Takayasu disease, GCA, PAN, GPA, MPA an EGPA according to individual international criteira. 2. Patients who will begin methotrexate, biologic agents, and immunosuppressants

Exclusion criteria

Exclusion criteria: Patients who thier physicians consider as not appropriate

Design outcomes

Primary

Measure	Time frame
efficacy at week 14	—

Countries

Japan

Contacts

Public ContactYuko Kaneko

Keio University School of Medicine Division of Rheumatology, Department of Internal Medicine

ykaneko@z6.keio.jp03-3353-1211

Outcome results